A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Myelofibrosis is a serious condition with limited treatment options.
• Ruxolitinib is a selective inhibitor of Janus kinase (JAK) 1 and 2.
• Ruxolitinib has demonstrated clinical activity in myelofibrosis.

Purpose of the Study:

• To evaluate the efficacy and safety of ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis.
• To assess the impact of ruxolitinib on spleen volume, symptom burden, and overall survival.

Main Methods:

• A double-blind, randomized trial comparing oral ruxolitinib to placebo in 309 patients.
• The primary endpoint was spleen volume reduction of 35% or more at 24 weeks via MRI.
• Secondary endpoints included response durability, symptom score changes, and overall survival.

Main Results:

• 41.9% of ruxolitinib patients achieved the primary endpoint vs. 0.7% for placebo (P<0.001).
• Ruxolitinib significantly improved total symptom score (45.9% vs. 5.3%, P<0.001) and overall survival (HR 0.50, P=0.04).
• Anemia and thrombocytopenia were common but rarely led to discontinuation; two cases of acute myeloid leukemia transformation occurred in the ruxolitinib group.

Conclusions:

• Ruxolitinib offers significant clinical benefits for myelofibrosis patients, including reduced spleen size, improved symptoms, and enhanced survival.
• These benefits are accompanied by an increased incidence of anemia and thrombocytopenia, particularly early in treatment.
• The study highlights ruxolitinib's role in managing myelofibrosis, with careful monitoring for adverse events.